Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P05177

UPID:
CP1A2_HUMAN

ALTERNATIVE NAMES:
CYPIA2; Cholesterol 25-hydroxylase; Cytochrome P(3)450; Cytochrome P450 4; Cytochrome P450-P3; Hydroperoxy icosatetraenoate dehydratase

ALTERNATIVE UPACC:
P05177; Q16754; Q6NWU3; Q6NWU5; Q9BXX7; Q9UK49

BACKGROUND:
The enzyme Cytochrome P450 1A2, also referred to as Cytochrome P450-P3 or Hydroperoxy icosatetraenoate dehydratase, is integral to the oxidative metabolism of both endogenous substrates and xenobiotics. It is known for its role in the hydroxylation of carbon-hydrogen bonds and the oxidative transformation of all-trans retinol to all-trans retinoic acid. The enzyme's preference for the (R,S) stereoisomer in the epoxidation of polyunsaturated fatty acids (PUFA) and its participation in eicosanoids metabolism underscore its biochemical versatility.

THERAPEUTIC SIGNIFICANCE:
The exploration of Cytochrome P450 1A2's functions offers promising pathways for therapeutic innovation. Its critical role in the biosynthesis of active forms of vitamins and in the metabolism of pharmaceuticals and toxins positions it as a key target in the design of drugs aimed at enhancing metabolic processes and detoxification, paving the way for breakthroughs in treatment modalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.